In joining the database, PointClickCare will mitigate an important gap in researchers' understanding of COVID-19: specifically, how the disease impacts patients who are receiving care in post-acute care settings.
The database is a cross-industry collaboration made up of research groups and various leading healthcare corporations all focused on solving questions related to COVID-19, such as evaluations of drug effectiveness utilizing de-identified electronic health record and claims data, identifying which demographic factors and pre-existing conditions are most closely correlated with ventilator support or excess mortality, and measuring the public health impact of quarantine measures put in place in different geographies.
The scientific steering committee, composed of leading academic researchers from numerous institutions and chaired by Mark Cullen, the Founding director of the Center for Population Health Sciences and a Professor of Medicine, Biomedical Data Science, and Health Research and Policy at Stanford University, has received more than 150 study proposals.
Early studies coming out of the database have analyzed the optimal policy structure to mitigate spread, examined mortality by demographic group, and analyzed how COVID-19 has changed the utilization of non-COVID-19 related healthcare services.
Senior care insights will be made possible by Lighthouse, PointClickCare's initiative aimed at providing healthcare organizations, government agencies and life sciences companies with de-identified data from consenting providers regarding older adults.
Lighthouse's mission is to provide data and insights that specifically represent seniors, a population often considered to be at higher risk for severe illness, and to support research by expanding drug discovery and development.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA